This is a multicenter, open, phase II clinical trial to evaluate the safety and efficacy of
almonertinib combined with pyrrolitinib in locally advanced or metastatic NSCLC patients with
her-2 variants detected after first-line EGFR-TKI treatment resistance. Patients with
first-line EGFR-TKI resistance showed HER-2 variation (including mutation and amplification)
in tissue or blood tests, and the treatment regimen of metinil combined with pyrrolitinib was
performed to evaluate the safety and efficacy of the treatment regimen. To determine the
optimal dose of pyrrolitinib, three dose groups of 240mg, 320mg, and 400mg were set, and the
"3+3" study design principle was adopted. About 27-36 people will be included in the study
(depending on the progress of the study)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.